Aptamer Group to host webinar and Q&A session for investors

Aptamer Group plc (LON: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, has announced that Dr Arron Tolley, Chief Executive Officer and Dr David Bunka, Chief Scientific Officer will be hosting a webinar on Thursday, 12 December 2024 at 6.00 pm (GMT).

The webinar will provide investors with a valuable opportunity to interact with Aptamer Group and gain insights into recent announcements.

There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

You can register for the event by using the following link:

https://www.turnerpope.com/register/

We are delighted to announce that the webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company’s broker, Turner Pope Investments.

Share on:

Written by: Amilia Stone

Latest Company News

Aptamer Group retail offer raises £274,000, total fundraise reaches £4.5 million

March 31, 2026

Aptamer Group said its retail offer closed having raised about £274,000 before expenses. Subject to shareholder approval at the general meeting on 13 April 2026, the company expects to issue 45.7 million shares at 0.6p each, bringing total gross proceeds from the placing, subscription and retail offer to about £4.5 million.

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

March 26, 2026

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million by issuing up to 83.3 million new ordinary shares at 0.6 pence each, with one warrant for every three shares subscribed.

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

March 25, 2026

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset development. The company also announced a bookbuild expected to raise at least £3.75 million to extend cash runway into 2028.

Aptamer expands pipeline with targeted radiopharmaceutical initiative

March 18, 2026

Aptamer Group is developing a proprietary radiopharmaceutical pipeline using its Optimer® platform, supported by a partnership with Radiopharmium Ltd and early data indicating improved radioligand stability compared to existing approaches.

Aptamer and Metir advance real-time water pathogen detection programme

February 17, 2026

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system.

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

February 11, 2026

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows.

Aptamer Group to host webinar and Q&A session for investors

We’ll keep you in the loop!

Latest Company News

Search

Follow us on Social Media: